Advertisement

Analysis of Endothelins by Enzyme-Linked Immunosorbent Assay and Radioimmunoassay

  • Anthony P. Davenport
  • Rhoda E. Kuc
Protocol
  • 419 Downloads
Part of the Methods in Molecular Biology™ book series (MIMB, volume 206)

Abstract

This chapter describes procedures for the measurement of endothelin peptides by antibodies, focusing on the two main immunoassay techniques that are widely used. In a two-site “sandwich” enzyme-linked immunosorbent assay (ELISA) one antibody is immobilized to a solid phase and captures the endothelin (ET) peptide(s), which is quantified by the binding to this complex of a second, enzyme-labeled antibody in the liquid phase. In a radioimmunoassay (RIA), the ET peptide(s) to be measured competes for the binding of a fixed concentration of radiolabeled peptide to a fixed concentration of antibody in the liquid phase. In contrast to the ELISA, the immune complex measured in a RIA does not contain the analyte and therefore inverse (falling) standard curves of peptide concentration vs bound labeled peptide are produced. For a more detailed discussion of the two techniques, refs. 1 and 2 are recommended.

Keywords

Brain Natriuretic Peptide Amersham Pharmacia Biotech Sandwich ELISAs Magnetic Rack Vasoactive Intestinal Contractor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Gosling J.P. (ed.) (2000) ELISA Immunoassays. OUP, Oxford, UK.Google Scholar
  2. 2.
    Chard T. (1990) An Introduction to Radioimmunoassay and Related Techniques. (Burton R.H. and van Knippenberg P.H., eds.) Elsevier, Amsterdam, The Netherlands.Google Scholar
  3. 3.
    Davenport A.P. and Russell F.D. (2001) Endothelin converting enzymes and endothelin receptor localization in human tissues, in Handbook Exp. Pharmacol. vol.152 (Warner T.D., ed.), Springer-Verlag, Berlin, Germany, pp.209-237.Google Scholar
  4. 4.
    Russell F.D., Skepper J.N., and Davenport A.P. (1998) Human endothelial cell storage granules:a novel intracellular site for isoforms of the endothelin converting enzyme. Circ. Res. 83, 314–321.PubMedGoogle Scholar
  5. 5.
    Haynes W.G. and Webb D.J. (1994) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344, 852–854.PubMedCrossRefGoogle Scholar
  6. 6.
    Bacon C.R., Cary N.R.B., and Davenport A.P. (1996) Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ. Res. 79, 794–801.PubMedGoogle Scholar
  7. 7.
    Kurihara H., Yoshizumi M., Sugiyama T., Yamaoki K., Nagai R., Takaku F., Satih H., Inui J., Yanagisawa M., and Masaki T. (1989) The possible role of endothelin-1 in the pathogenesis of coronary vasospasm. J. Cardiovasc. Pharmacol. 13(Suppl 5), S132–S137.PubMedCrossRefGoogle Scholar
  8. 8.
    Wei C.M., Lerman A., Rodeheffer R.J., McGregor C.G., Brandt R.R., Wright S., et al. (1994) Endothelin in human congestive heart failure. Circ. 89(4), 1580–1586.Google Scholar
  9. 9.
    Monge J.C. (1998) Neurohormonal markers of the clinical outcome of cardiovascular disease:is endothelin the best one? J. Cardiovasc. Pharmacol. 32(Suppl 2), S36–S42.PubMedGoogle Scholar
  10. 10.
    O’ Reilly G., Charnock-Jones D.S., Morrison J.J., Cameron I.T., Davenport A.P., and Smith S.K. (1993) Alternatively spliced mRNA’ s for human endothelin-2 and their tissue distribution. Biochem. Biophys. Res. Commum. 193, 834–840.CrossRefGoogle Scholar
  11. 11.
    Plumpton C., Ashby M.J., Kuc R.E., O’ Reilly G., and Davenport A.P. (1996) Expression of endothelin peptides and mRNA in the human heart. Clin. Sci. 90, 37–46.PubMedGoogle Scholar
  12. 12.
    Maguire J.J. and Davenport A.P. (1995) ETA receptors mediate the constrictor responses to endothelin peptides in human blood vessels in vitro. Br. J. Pharmacol. 115, 191–197.PubMedGoogle Scholar
  13. 13.
    Howard P.G., Plumpton C., and Davenport A.P. (1992) Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J. Hypertens. 10, 1379–1386.PubMedCrossRefGoogle Scholar
  14. 14.
    Matsumoto H., Suzuki N., Kitada C., and Fujino M. (1994) Endothelin family peptides in human plasma and urine:their molecular forms and concentrations. Peptides 15, 505–510.PubMedCrossRefGoogle Scholar
  15. 15.
    Plumpton C., Champeney R., Ashby M.J., Kuc R.E., and Davenport A.P. (1993) Characterisation of endothelin isoforms in human heart:Endothelin-2 demonstrated. J. Cardiovasc. Pharmacol. 22(Suppl 8), 26–28.CrossRefGoogle Scholar
  16. 16.
    Suzuki N., Matsumoto H., Miyauchi T., Goto K., Masaki T., Tsuda M., and Fujino M. (1990) Endothelin-3 concentrations in human plasma:increased concentrations in patients undergoing haemodialysis. Biochem. Biophys. Res. Commum. 169, 809–815.CrossRefGoogle Scholar
  17. 17.
    Davenport A.P., Plumpton C., Ferro C.J., Webb D.J., and Horton J. (1998) Systemic infusion of an endothelin receptor antagonist increases plasma ET-3 in humans. Br. J. Pharmacol. 123, 290P.CrossRefGoogle Scholar
  18. 18.
    Takahashi K., Ghatei M.A., Jones P.M., Murphey J.K., Lam H.C., O’Haloran D.J., and Bloom S.R. (1991) Endothelin in human brain and pituitary gland:presence of immunoreactive endothelin, endothelin messenger ribonucleic acid, and endothelin receptors. J. Clin. Endocrinol. Metab. 72, 693–699.PubMedCrossRefGoogle Scholar
  19. 19.
    Plumpton C., Horton J., Kalinka K.S., Martin R. and Davenport A.P. (1994) Effects of phosphoramidon and pepstatin A on the secretion of endothelin-1 and big endothelin-1 in human umbilical vein endothelial cells:Measurement by two-site ELISAs. Clin. Sci. 87, 245–251.PubMedGoogle Scholar
  20. 20.
    Davenport A.P., Ashby M.J., Easton P., Ella S., Bedford J., Dickerson C., et al. (1990) A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma:comparison of levels in essential hypertension and normotensive controls. Clin. Sci. 78, 261–264.PubMedGoogle Scholar
  21. 21.
    Plumpton C., Haynes W.G., Webb D.J., and Davenport A.P. (1995) Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br. J. Pharmacol. 115, 1821–1828.Google Scholar
  22. 22.
    Plumpton C., Haynes W.G., Webb D.J., and Davenport A.P. (1995) Measurement of C-terminal fragment of big endothelin-1:A novel method for assessing the generation of endothelin-1 in human. J. Cardiovasc. Pharmacol. 26(Suppl 3), S34–S36.PubMedGoogle Scholar
  23. 23.
    Plumpton C., Ferro C.J., Haynes W.G., Webb D.J., and Davenport A.P. (1996) The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal induced by systemic administration of the endothelin antagonist TAK-044. Br. J. Pharmacol. 119, 311–314.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2002

Authors and Affiliations

  • Anthony P. Davenport
    • 1
  • Rhoda E. Kuc
    • 1
  1. 1.Clinical Pharmacology UnitUniversity of CambridgeCambridgeUK

Personalised recommendations

Cite protocol

Buy options